The classic caries clinical trial: Constraints and opportunities

Journal of Dental Research

Volumn 83, Issue SPEC. ISS. C, 2004, Pages

  Stamm, J W ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Caries prevention; Clinical trial

Indexed keywords

CLASSIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DENTAL CARIES; ETHICS; HUMAN; META ANALYSIS; METHODOLOGY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

CLINICAL TRIALS; DENTAL CARIES; HUMANS; META-ANALYSIS; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 4143152006     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/154405910408301S02     Document Type: Conference Paper

References (106)

1. Amberson JB Jr, McMahon BT, Pinner M (1931). A clinical trial of sanocrysin in pulmonary tuberculosis. Am Rev Tuberc 24:401-435.
2. Beacham BE, Kurgansky D, Gould WM (1990). Circumoral dermatitis caused by tartar control dentifrices. J Am Acad Dermatol 22:1029-1032.
3. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. (1996). Improving the quality of reporting of randomized controlled trials. J Am Med Assoc 276:637-639.
4. Bell RM, Klein SP (1984). Management and evaluation of the effects of misclassification in a controlled clinical trial. J Dent Res 63(Spec Iss):731-734.
5. Blackwelder WC (1982). 'Proving the null hypothesis' in clinical trials. Controlled Clin Trials 3:345-353.
6. Blackwelder WC (2001). Equivalence trials. In: Biostatistics in clinical trials. Redmond CK, Colton T, editors. New York: Wiley, pp. 179-185.
7. Blackwelder WC, Chang MA (1984). Sample size graphs for 'proving the null hypothesis'. Controlled Clin Trials 5:97-105.
8. Brittain E, Wittes J (1989). Factorial designs in clinical trials: the effectiveness of non-compliance and subadditivity. Stat Med 8:161-171.
9. Brown BW (1980). The crossover experiment for clinical trials. Biometrics 36:69-80.
10. Buck C, Donner A (1982). The design of controlled experiments in the evaluation of non-therapeutic interventions. J Chron Dis 35:531-538.
11. Bull JP (1959). The historical development of clinical therapeutic trials. J Chron Dis 10:218-248.
12. Caplan DJ, Slade GD, Biesbrock AR, Bartizek RD, McClanahan SF, Beck JD (1999). A comparison of increment and incidence density analyses in evaluating the anticaries effects of two dentrifices. Caries Res 33:16-22.
13. CAPS Investigators (1994). The cardiac arrhythmia pilot study. Am J Cardiol 57:91-95.
14. Carriere KC (1994). Crossover designs for clinical trials. Stat Med 13:1063-1069.
15. Chalmers TC (1993). Meta-analytic stimulus for changes in clinical trials. Stat Methods Med Res 2:161-172.
16. Chesters RK, Pitts NB, Matuliene G, Kvedariene A, Huntington E, Bendinskaite R, et al. (2002). An abbreviated caries clinical trial design validated over 24 months. J Dent Res 81:637-640.
17. Chilton NW, Fertig JW (1958). Clinical dental trial. I. A new caries-inhibitory agent. J Dent Res 37:335-350.
18. Chow SC, Liu J (1992). Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker.
19. CIOMS/WHO (1993). International ethical guidelines for biomedical research involving human subjects. Geneva: CIOMS.
20. Clark DC, Mechanic M, Banting DW (1982). A further look at the role of radiographs in trials of caries-prophylactic agents. J Pub Health Dent 42:237-250.
21. Clark DC, Hanley JA, Weinstein PL, Stamm JW (1985). An empirically based system to estimate the effectiveness of caries preventive agents. Caries Res 19:83-95.
22. Cohen J (1994). Clinical trial monitoring: hit or miss? Science 264:1534-1537.
23. Cornfield J (1978). Randomization by group: a formal analysis. Am J Epidemiol 108:100-102.
24. Council on Dental Therapeutics (1988). Report of workshop aimed at defining guidelines for caries clinical trials: superiority and equivalency claims for anticaries dentifrices. J Am Dent Assoc 117:663-665.
25. D'Agostino RB, Massaro JM (2004). New developments in medical clinical trials. J Dent Res 83(Spec Iss C):C18-C24.
26. Daniels M, Hill AB (1952). Chemotherapy of pulmonary tuberculosis in young adults: an analysis of the combined results of three medical research council trials. Br Med J 1:1162-1168.
27. DeLattre VF (1999). Factors contributing to adverse soft tissue reactions due to the use of tartar control toothpastes: report of a case and literature review. J Periodontol 70:803-807.
28. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials 7:177-188.
29. Donner A, Birkett N, Buck C (1981). Randomization by cluster: sample size requirements and analysis. Am J Epidemiol 114:906-914.
30. Downer MC, Worthington HV (1992). The status of bite-wing radiographs in enhancing discriminatory ability in prophylactic clinical trials. Caries Res 26:195-200.
31. Egger M, Juni P, Bartlett C (2001). Value of flow diagrams in reports of randomized controlled trials. J Am Med Assoc 285:1996-1999.
32. Enas GG, Dornseif BE, Sampson CB, Rockhold FW, Wuu J (1989). Monitoring versus interim analysis of clinical trials: a perspective from the pharmaceutical industry. Cont Clin Trials 10:57-70.
33. Ferlito TA (1992). Tartar-control toothpaste and perioral dermatitis. J Clin Orthod 26:43-44.
34. Firestone AR, Sema D, Heaven TJ, Weems RA (1998). The effect of a knowledge-based, image analysis and clinical decision support system on observer performance in the diagnosis of approximal caries from radiographic images. Caries Res 32:127-134.
35. Fisher RA (1925). Statistical methods for research workers. Edinburgh: Oliver & Boyd.
36. Fisher RA (1926). The arrangement of field experiments. J Min Agric G Br 33:503-513.
37. Fleiss JL (1982). Multicentre clinical trials: Bradford Hill's contributions and some subsequent developments. Stat Med 1:353-359.
38. Fleiss J (1984). Assessing treatment effects in caries trials using ordered categorical data. J Dent Res 63(Spec Iss):778-782.
39. Fleiss J (1986). Analysis of data from multiclinic trials. Control Clin Trials 7:267-275.
40. Fleiss JL, Fischman SL, Chilton NW, Park MH (1979). Reliability of discrete measurements in caries trials. Caries Res 13:23-31.
41. Freedman B (1987). Equipoise and the ethics of clinical research. N Engl J Med 317:141-145.
42. Friedman LM, Furberg CD, DeMets DL (1996). Fundamentals of clinical trials. 3rd ed. St. Louis: Mosby.
43. Geary DN, Huntington E, Gilbert RJ (1992). Analysis of multivariate data from four dental clinical trials. J R Statist Soc A 155:77-89.
44. Gillum RF, Williams PT, Sondike E (1980). Some considerations for the planning of the total community prevention trials - when is sample size adequate? J Community Health 5:270-278.
45. Gould L (1998). Multi-centre trial analysis revisited. Stat Med 17:1779-1797.
46. Grainger DJ, Lehnoff RW, Bollmer BW, Zacherl WA (1984). Analysis of covariance in dental caries clinical trials. J Dent Res 63(Spec Iss):766-771.
47. Hannigan A, O'Mullane DM, Barry D, Schafer R, Roberts AJ (2001). A reanalysis of a caries clinical trial by survival analysis. J Dent Res 80:427-431.
48. Hannigan A (2004). Using survival methodologies in demonstrating caries efficacy. J Dent Res 83(Spec Iss C):C99-C102.
49. Heifetz SB (1983). Ethical considerations and study design. Proceedings of the Conference on Caries Clinical Trials. Chicago, IL: American Dental Association.
50. Hill AB (1952). The clinical trial. N Engl J Med 247:113-119.
51. Hujoel PP, Isokangas PJ, Tiekso J, Davis S, Lamont RJ, DeRouen TA, et al. (1994). A re-analysis of caries rates in a preventive trial using Poisson regression models. J Dent Res 73:573-579.
52. Hunt RJ (1986). Percent agreement, Pearson's correlation, and kappa as measures of inter-examiner reliability. J Dent Res 65:128-130.
53. Imrey PB, Kingman A (2004). Analysis of clinical trials involving noncavitated caries lesions. J Dent Res 83(Spec Iss C):C103-C108.
54. Jadad A (1998). Randomized controlled trials. London: BMJ Books.
55. James KE, Forrest WH Jr, Rose RL (1985). Crossover and noncrossover designs in four-point parallel line analgesic assays. Clin Pharmacol Ther 37:242-252.
56. Johnson MF (1993). Comparative efficacy of NaF and SMFP dentifrices in caries prevention: a meta-analytic overview. Caries Res 27:328-336.
57. Johnson MF (2004). The role of risk factors in the identification of appropriate subjects for caries clinical trials: validity and efficiency considerations. J Dent Res 83(Spec Iss C):C116-C118.
58. Jones B, Jarvis P, Lewis JA, Ebbutt AF (1996). Trials to assess equivalence: the importance of rigorous methods. Br Med J 313:36-39.
59. Katz BP, Huntington E (2004). Statistical issues for combining multiple caries diagnostics for demonstrating caries efficacy. J Dent Res 83(Spec Iss C):C109-C112.
60. Kingman A (1977). Adequate cohort sizes for caries clinical trials. Community Dent Oral Epidemiol 6:30-35.
61. Kingman A (1978). A method of utilizing the subjects' initial caries experience to increase efficiency in caries clinical trials. Biometry Section, National Caries Program. Bethesda, MD: National Institute of Dental Research.
62. Kingman A (1984). Stratification methods in caries clinical trials. J Dent Res 63(Spec Iss):773-777.
63. Kingman A (1992). Specific statistical considerations relevant to the design and analysis of gingivitis trials demonstrating product superiority or equivalence. J Periodontal Res 27:378-389.
64. Klein H, Palmer CE, Knutson JW (1938). Studies on dental caries, dental status and dental needs of elementary school children. Pub Health Reports 53:751-765.
65. Klein SP, Bell RM, Bohannan HM, Disney JA, Wilson A (1984). The reliability of clinical and radiographic examinations in the national preventive dentistry demonstration program. Santa Monica, CA: Rand Corp.
66. Koch GG, Amara IA, Brown BW Jr, Colton T, Gillings DB (1989). A two-period crossover design for the comparison of two active treatments and placebo. Stat Med 8:487-504.
67. Kowitz G, Jacobsen J, Meng Z, Lucatorto F (1990). The effects of tartar-control toothpaste on the oral soft tissues. Oral Surg Oral Med Oral Pathol 70:529-536.
68. Lachin JM (1981). Introduction to sample size determination and power analysis for clinical trials. Controlled Clin Trials 2:93-113.
69. Leske GS, Ripa LW (1980). Ethical and legal considerations associated with clinical field trials. J Dent Res 59(Spec Iss C):1243-1253.
70. Levine RJ (1986). Ethics and regulation of clinical research. 2nd ed. Munich: Urban & Schwarzenberg.
71. Levine RJ, Dennison DK (1997). Randomized clinical trials in periodontology: ethical considerations. Ann Periodontol 2:83-94.
72. Louis TA, Lavori PW, Bailar JC III, Polansky M (1984). Crossover and self-controlled designs in clinical research. N Engl J Med 310:24-31.
73. Makuch R, Simon R (1978). Sample size requirements for evaluating a conservative therapy. Cancer Treatment Reports (62)7:1037-1040.
74. Mancl LA, Hujoel PP, DeRouen TA (2004). Efficiency issues among statistical methods for demonstrating efficacy of caries prevention. J Dent Res 83(Spec Iss C):C95-C98.
75. Marks RG (2004). The future of web-based clinical research in dentistry. J Dent Res 83(Spec Iss C):C25-C28.
76. McClendon BJ, Driscoll WS, Abrams AM, Barbano JP (1972). A procedure for estimating sample size in clinical trials of dental caries preventives. J Dent Res 51:1589-1593.
77. Medical Research Council (1948). Streptomycin treatment of pulmonary tuberculosis. Br Med J 2:769-782.
78. Meinert CL (1981). Organization of multicenter clinical trials. Controlled Clin Trials 1:305-312.
79. Meinert CL (1986). Clinical trials: design, conduct and analysis. New York: Oxford.
80. Meinert CL (1998). Beyond CONSORT: need for improved reporting standards for clinical trials. J Am Med Assoc 278:1487-1489.
81. Moher D, Schulz KF, Altman DG, Lepage L, (2001a). Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. J Am Med Assoc 285:1992-1995.
82. Moher D, Schulz KF, Altman DG (2001b). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 134:657-662.
83. Navazesh M (1995). Tartar-control toothpaste as a possible contributory factor in the onset of superficial mucocele: a case report. Spec Care Dentist 15:74-78.
84. Needleman I (1999). CONSORT. Consolidated standards of reporting trials (editorial). Br Dent J 186:207.
85. O'Mullane DM (1976). Efficiency in clinical trials of caries preventive agents and methods. Community Dent Oral Epidemiol 4:190-194.
86. Petitti DB (2000). Meta-analysis, decision analysis, and cost-effectiveness analysis. Methods for quantitative synthesis in medicine. 2nd ed. New-York: Oxford University Press.
87. Pledger GW (1992). Basic statistics: importance of adherence. J Clin Res Pharmacoepidemiol 6:77-81.
88. Pocock SJ (1983). Clinical trials: a practical approach. New York: Wiley.
89. Proskin HM, Kingman A, Naleway C, Wozniak WT (1995). Comparative attributes for the description of the relative efficacy of therapeutic agents: general concepts and definitions, and application to the American Dental Association guidelines for the comparison of the clinical anticaries efficacy of fluoride dentifrices. J Clin Dent 6:176-184.
90. Radike AW (1972). Examiner error and reversals in diagnosis. In: Proceedings of the conference on the clinical testing of cariostatic agents. Chicago, IL: American Dental Association.
91. Richards D, Lawrence A, Sackett DL (1997). Bringing an evidence-base to dentistry. Community Dent Health 14(2):63-65.
92. Schuirmann DJ (1987). A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15:657-680.
93. Schwartz D, Lellouch J (1967). Explanatory and pragmatic attitudes in therapeutical trials. J Chron Dis 20:637-648.
94. Senn S (1998). Some controversies in planning and analyzing multi-centre trials. Stat Med 17:1753-1765.
95. Shapiro SH, Glass KC (2000). Why Sackett's analysis of randomized controlled trials fails, but needn't. Canadian Med Assoc J 163:834-835.
96. Slack GL, Martin WJ (1964). The use of a dentifrice containing stannous fluoride in the control of dental caries. Br Dent J 117:275-280.
97. Straus SE, Sackett DL (1998). Using research findings in clinical practice. BMJ 317(7154):339-342.
98. US Department of Health and Human Services (1991). National Institutes of Health OPRR Reports: Code of Federal Regulations: (45 CFT 46) Protection of Human Subjects (http://ohrp.osophs.dhhs.gov/polasur.htm).
99. Weijer C, Shapiro SH, Glass KC (2000). Why clinical equipoise, and not the uncertainty principle, is the moral underpinning of the RCT. BMJ 321:756-758.
100. Weinstein P, Milgrom P, Sanghvi H (1995). Recruitment issues: errors of omission in dental research. J Dent Res 74:1028-1029.
101. Wenzel A, Anthonisen PN, Juul MB (2000). Reproducibility in the assessment of caries lesion behavior: a comparison between conventional film and subtraction radiography. Caries Res 34:214-218.
102. Whitehead J (1986). Sample sizes for phase II and phase III clinical trials: an integrated approach. Stat Med 5:459-464.
103. Wiens BL, Iglewicz B (2000). Design and analysis of three treatment equivalence trials. Control Clin Trials 21:127-137.
104. Williams JE, Donnelly CJ, Fulton JT (1967). An appraisal of the necessity for radiographs in clinical trials of caries-inhibitory agents. J Pub Health Dent 21:54-62.
105. www.cochrane.org/cochrane/cc-broch.htm#BDL, March (2002).
106. Zeisel H (1970). Reducing the hazards of human experiments through modifications in research design. Ann NY Acad Sci 169:475-486.